Article info
PDFNeurological rarities
Mesothelioma and anti-Ma paraneoplastic syndrome; heterogeneity in immunogenic tumours increases
- Correspondence to Dr Hilary Archer, Department of Neurosciences, Frenchay Hospital, Frenchay Park Road, Bristol, UK, BS16 1LE; hilary.archer{at}nbt.nhs.uk
Citation
Mesothelioma and anti-Ma paraneoplastic syndrome; heterogeneity in immunogenic tumours increases
Publication history
- First published June 8, 2013.
Online issue publication
April 14, 2016
Article Versions
- Previous version (14 April 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions
Other content recommended for you
- Anti-Ma and anti-Ta associated paraneoplastic neurological syndromes: 22 newly diagnosed patients and review of previous cases
- Which antibody and which cancer in which paraneoplastic syndromes?
- Republished: Which antibody and which cancer in which paraneoplastic syndromes?
- Paraneoplastic encephalitis: clinically based approach on diagnosis and management
- Paraneoplastic neurological syndromes: a practical approach to diagnosis and management
- Opsoclonus-myoclonus paraneoplastic syndrome in nasopharyngeal carcinoma
- Cerebrospinal fluid study in paraneoplastic syndromes
- Plasma exchange in neurological disease
- Recurrent angiosarcoma of scalp with opsoclonus myoclonus syndrome: role of salvage treatment
- Central nervous system neuronal surface antibody associated syndromes: review and guidelines for recognition